Ryo Hanajiri

7PUBLICATIONS
29CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 11, 2026
CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis.

Yuki Takeuchi, Seitaro Terakura, Kohei Ishigiwa

|May 25, 2025
Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion.

Ryo Hanajiri, Hiroya Wakabayashi, Kohei Ishigiwa

|May 09, 2025
Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells.

Masahide Osaki, Seitaro Terakura, Shiho Hirano

|Feb 27, 2025
Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever.

Hiroya Wakabayashi, Seitaro Terakura, Kohei Ishigiwa

|Oct 13, 2023
Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models.

Kanae Imai, Yuki Takeuchi, Seitaro Terakura

Pageof 2